• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Frazier Healthcare acquires U.S. packaging operations from Catalent

Frazier Healthcare acquires U.S. packaging operations from Catalent

June 20, 2012
CenterWatch Staff

Somerset, N.J.-based Catalent Pharma Solutions has closed the purchase and sale of its U.S. commercial pharmaceutical packaging operations based in Philadelphia, Penn., and Woodstock, Ill., to Frazier Healthcare.

The business will be operated as Packaging Coordinators (PCI). The former president of the business (from 2002-2006), Bill Mitchell, will again take the helm as president and CEO. Re-joining Mitchell as part of the new PCI management team are Bill Bolding as COO and Phil DiGiacomo as vice president of sales, each of whom have a longstanding history of success in both the industry and with PCI.

"We are demonstrating our emphasis on a team approach at Frazier by empowering a known and passionate management team to create a reinvigorated model for healthcare packaging," said Alan Frazier, managing partner of Frazier Healthcare. "The acquisition of PCI gives us the opportunity to extend our model of uncovering opportunities where the combination of new a management team and an infusion of capital can result in outstanding growth and market leadership."

Catalent's decision to sell its U.S. commercial packaging operations is based on the company's business strategy to focus on growing its world leading businesses in development solutions and advanced delivery technologies, clinical trial supplies, advanced blow/fill/seal aseptic delivery technology, as well as offering integrated solutions for the development and supply of injectable biologics and complex pharmaceutical products. The acquisition does not involve Catalent's clinical supply services operations adjacent to the Red Lion Road facility in Philadelphia, nor the blow/fill/seal business in Woodstock.

"This second act for PCI is not about nostalgia. We want to build on a strong foundation and reinvigorate PCI to once again become the supplier of choice for outsourced healthcare packaging," said Bill Mitchell, president and CEO of PCI. "This management team knows growth is about focusing on the customer, including their mission critical milestones, timelines and business needs. The products create and drive the opportunity. The attention to quality and the focus on meeting the customers’ current and future needs will drive our growth."

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing